A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

In the media

Read how the global media covers how pharmaceutical companies respond to market trends and global health issues using the Foundation's research, and translates the complexity of access to medicine for the public.

All Access to Medicine Foundation Access to Medicine Index Antimicrobial Resistance Benchmark Access to Vaccines Index

23 Jan 2018

New Index Rates Drug Companies in Fight Against ‘Superbugs’

Donald McNeil of The New York Times reports on the results of the Antimicrobial Resistance Benchmark and the companies who are tackling the growing “s...

23 Jan 2018

Tracking Big Pharma’s Progress on AMR

Jim O’Neill, former chair of the AMR review, reports on the role of the Benchmark to make progress on the crucial public-health issue of AMR.

23 Jan 2018

Number of new antibiotics has fallen sharply since 2000

The Guardian reports on the results of the Antimicrobial Resistance Benchmark with a focus on the number of new antibiotics being developed.

23 Jan 2018

GSK leads drugmakers’ fight against superbugs

Clive Cookson, Science Editor of The Financial Times, reports on the companies who are most active in curbing AMR. Cookson covers the Antimicrobi...

23 Jan 2018

Drug companies told to do more to tackle ‘superbug’ crisis

Ben Hirschler reports on the publication of the first Antimicrobial Resistance Benchmark.

23 Jan 2018

Der ernüchternde Kampf gegen die Killerkeime

Anja Ettel reports on the role of the pharmaceutical industry in the fight against resistant pathogens.

23 Jan 2018

Drug companies are starting to tackle antimicrobial resistance but could do more, report shows

The British Medical Journal reports on the results of the AMR Benchmark and discusses some of the Key Findings of the report.

23 Jan 2018

Ohne Antibiotika keine Gesundheitssysteme

Andreas Schwander of the Basler Zeitung reports on the results of the Antimicrobial Resistance Benchmark and the importance of access to antibiotics.

23 Jan 2018

Responsible Investor reports on the AMR Benchmark

Responsible Investor ESG Briefing reports on the publication of the first-ever AMR Benchmark.

23 Jan 2018

Goede antiresistentie-maatregelen farmaceut moet concurrent inspireren

NOS takes a look at the Antimicrobial Resistance Benchmark and the current TB landscape in the Netherlands.

23 Jan 2018

This new index ranks companies’ efforts in the fight against antimicrobial resistance

Science Mag covers the Benchmark Performance and the efforts to make drugs available to populations who need them most, and ‘stewardship,’ which inclu...

23 Jan 2018

Johnson & Johnson and GSK leaders in antibiotics research – report

Pharmaphorum reports on the leaders of the AMR Benchmark and the call for further action to combat the rise of drug-resistant bacteria.

23 Jan 2018

Benchmark for tracking industry efforts to fight antimicrobial resistance launched at WEF in Davos

Gareth Macdonald reports on the launch of the Benchmark at the World Economic Forum in Davos, Switzerland.

23 Jan 2018

Eerste Antimicrobial Resistance Benchmark gelanceerd

The Dutch Association Innovative Medicines covers the publication of the first Antimicrobial Resistance Benchmark and its key findings.

23 Jan 2018

Watch: Chống siêu vi khuẩn kháng thuốc kháng sinh

Vietnam Television (VTV) reports on the results of the AMR Benchmark with insight from Jayasree Iyer live at the WEF, Davos.

23 Jan 2018

Antibiotics need to be manufactured, marketed responsibly: Expert

The New Indian Express reports on the launch of the first Antimicrobial Resistance Benchmark at the WEF, Davos.

Got a question?

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |